Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beta Bionics filings document a Nasdaq-listed medical device issuer commercializing diabetes-management technology for insulin-requiring people. Recent Form 8-K reports provide results of operations, financial condition, guidance-related exhibits, channel metrics for Durable Medical Equipment and Pharmacy Benefit Plan reimbursement, and disclosures tied to iLet Bionic Pancreas data and investor presentations.
The company’s proxy materials cover annual meeting matters, board-class director elections, auditor ratification, voting mechanics, and stockholder governance. Other material-event filings disclose FDA inspection correspondence involving Quality Management System, Medical Device Reporting, and Corrections and Removals, alongside the company’s registered common stock and public-company reporting status.
Michael Mensinger reported proposed sales of Common Stock on Form 144 relating to equity received for services to the issuer. The filing lists securities vested as Restricted Stock Units on 03/01/2026 and shows multiple sales in the past three months.
The filing records sales of 1,063 shares on 12/02/2025, 7,200 shares on 01/02/2026, 600 shares on 01/02/2026, and 2,200 shares on 01/06/2026, with amounts shown alongside each entry.
Stephen Feider submitted a Form 144 notice reporting proposed sales of Common Stock tied to Beta Bionics, Inc./BBNX. The filing lists Restricted Stock Units vesting under a registered plan dated 03/01/2026 and shows prior sale entries dated 12/02/2025 and 01/02/2026.
Sean Saint reported a Form 144 sale notice relating to Common Stock of Beta Bionics, Inc. The filing lists 3,384 shares associated with restricted stock units vesting under a registered plan on 03/01/2026, with Morgan Stanley Smith Barney LLC named as broker on 03/02/2026.
The filing also shows prior sales of 3,278 shares on 12/02/2025 for $96,163.08. The securities are described as compensation for services rendered to the issuer.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported new equity awards and a small share sale. He received a grant of 109,105 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan and 58,749 stock options, which vest in 36 equal monthly installments starting on March 1, 2026.
On March 2, 2026, he sold 834 shares of common stock in an open-market transaction at a weighted average price of $12.3616, in a price range between $12.20 and $12.55, to cover tax withholding obligations tied to restricted stock unit vesting. After this sale, he directly owned 139,486 shares of common stock.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported multiple equity transactions. He sold 1,026 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share, with prices ranging from $12.20 to $12.55, to cover tax withholding obligations from vesting restricted stock units.
He also acquired 109,105 shares of common stock as a grant classified as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. In addition, he received an employee stock option covering 58,749 shares, which is scheduled to vest in 36 equal monthly installments starting from March 1, 2026.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a mix of equity grants and a small share sale. On February 27, 2026, he received a grant of 58,749 employee stock options and 109,105 shares of common stock at a price of $0.0000 per share, including a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The option award will vest in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,064 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share to cover tax withholding obligations associated with restricted stock unit vesting, leaving him with 188,793 common shares directly held after that sale.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported both stock awards and a small share sale. On February 27, 2026, he received 131,543 shares of common stock as restricted stock units and an option for 70,831 shares that vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,428 shares of common stock at a weighted average price of $12.3616 to cover tax withholding obligations related to restricted stock unit vesting, and held 172,729 common shares directly afterward.
Beta Bionics, Inc. President & CEO Sean Saint reported a mix of equity awards and a small tax-related share sale. On February 27, 2026, he acquired 343,269 shares of common stock as a restricted stock unit award under the 2025 Equity Incentive Plan and received an employee stock option for 184,837 shares, which vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 3,384 shares of common stock in an open-market transaction at a weighted average price of $12.3616, solely to cover tax withholding obligations from restricted stock unit vesting, and held 437,809 common shares directly afterward.
Beta Bionics, Inc. filed a shelf registration on Form S-3 to register securities for future offerings.
The prospectus describes that the company may offer common stock, preferred stock, debt securities and warrants from time to time, and that net proceeds are intended for general corporate purposes, including research and development, product enhancements and working capital. The company’s common stock trades on the Nasdaq Global Market under the symbol BBNX, and the prospectus cites a last reported sale price of $13.67 per share on February 23, 2026.
Beta Bionics, Inc. files its annual report outlining a fast-growing, but still early-stage, diabetes device business built around the iLet Bionic Pancreas. The iLet, an FDA-cleared fully closed-loop insulin delivery system for type 1 diabetes, launched commercially in May 2023 and reached an installed base of 35,011 devices as of December 31, 2025.
The company targets a large U.S. market of 1.9 million people with type 1 diabetes and an estimated 1.9 million insulin-intensive type 2 patients, aiming to simplify care by removing carb counting and manual dosing. Its strategy centers on focused U.S. commercialization, multi-channel reimbursement through both durable medical equipment and pharmacy benefits, and extensive third-party payor contracting.
Beta Bionics is investing in a pipeline that includes Mint, a tubeless patch pump aimed at a pharmacy-channel, pay-as-you-go model, and a bihormonal iLet system that delivers both insulin and glucagon, developed with Xeris. It also maintains key integrations with DexCom and Abbott CGM systems and holds a sizable patent estate, but highlights significant risks around continued losses, funding needs, competition from larger pump makers, regulatory obligations, product reliability, cybersecurity, and dependence on single-source suppliers and external partners.